← 返回

自组装微粒水凝胶支架构建人工三级淋巴结构以增强针对实体瘤的 CAR-T 细胞治疗

英文原题:Self-assembled microparticle hydrogel scaffolds to construct artificial tertiary lymphoids for enhanced CAR-T cell therapy against solid tumors.

查看英文原题

Self-assembled microparticle hydrogel scaffolds to construct artificial tertiary lymphoids for enhanced CAR-T cell therapy against solid tumors.

PubMed 2026/01/06(内容时间) Biomaterials Q1 · IF 13.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)T细胞疗法治疗血液系统恶性肿瘤疗效显著,但治疗实体瘤面临挑战,部分原因是有效免疫细胞向肿瘤内浸润有限,导致肿瘤内不同免疫细胞类型间相互作用不足。本研究开发了一种可注射支架,由带相反电荷的水凝胶微粒(HMP)组成,用于在肿瘤微环境中模拟三级淋巴结构(TLS)。将免疫刺激性细胞因子包封于HMP中,并将T细胞和B细胞装载在支架内HMP之间后,瘤内注射形成的人工TLS不仅可作为免疫刺激剂储库,还可促进B、T淋巴细胞间相互作用,支持T细胞持续扩增和活化。多个肿瘤模型显示,瘤内注射同时装载CAR-T 和B细胞的人工TLS,不仅有效抑制局部肿瘤,还产生显著远隔效应、抑制远处肿瘤;其治疗效果明显优于传统CAR-T 疗法。因此,本研究提出一种新策略:将免疫活化细胞装载于可注射水凝胶支架,构建人工TLS,以改善T细胞疗法治疗实体瘤的效果。

展开英文摘要原文

Chimeric antigen receptor (CAR)-T cell therapy while demonstrating remarkable efficacies in treating hematologic malignancies, has encountered challenges in solid tumor treatment, partly due to the limited intratumoral infiltration of effective immune cells and thus inefficient interactions between different immune cell types inside those tumors.

Herein, we develop an injectable scaffold based on hydrogel microparticles (HMPs) with opposite charges to replicate tertiary lymphoid structures (TLSs) within the tumor microenvironment. With encapsulation of immune-stimulating cytokines inside HMPs and loading of both T cells and B cells between HMPs in the scaffold, the artificial TLSs after intratumoral injection could not only serve as a depot of immunostimulants, but also promote intercellular interactions between B and T lymphocytes to support continuous T cell expansion and activation.

As demonstrated in several tumor models, our artificial TLSs loaded with both CAR-T cells and B cells after intratumoral injection could not only effectively suppress local tumors, but also present remarkable abscopal effects to inhibit distant tumors, presenting greatly enhanced therapeutic performance compared to conventional CAR-T therapy.

Our work thus presents a novel strategy to improve the efficacy of T-cell-therapies against solid tumors based on immune-activating cell-loaded injectable hydrogel scaffold as artificial TLSs.

论文信息

作者
Li Q、Xiao Z、Liu B、Xu Y、Wang C、Li M、Wu Y、Yin C
第一作者单位
Institute of Functional Nano and Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, Jiangsu, 215123, China.China
通讯作者单位
Institute of Functional Nano and Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, Jiangsu, 215123, China. Electronic address: ychao@suda.edu.cn.China
期刊
Biomaterials2026 Jun
原文标识
PubMed 41520540 · DOI 10.1016/j.biomaterials.2025.123976